Upadacitinib (LuciUpa) Overview LuciUpa, a 15 mg oral tablet by Lucius Pharmaceuticals, is used to treat moderate to severe rheumatoid arthritis and other autoimmune conditions. This selective JAK inhibitor reduces inflammation and provides rapid symptom relief. Side Effects: Commonly include nausea, headache, and elevated liver enzymes. #Upadacitinib #LuciUpa #RheumatoidArthritis #JAKInhibitor #AutoimmuneDisease #PatientCare #HealthcareInnovation #QualityOfLife #Medication #Pharmaceuticals | Lu

AbbVie : le médicament Upadacitinib atteint ses objectifs dans deux études de phase 3 sur le vitiligo

Diving into the Details of Upadacitinib for UC and Crohn’s Disease

European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis